Novo Nordisk suspended from UK trade body after marketing code breach

16 March 2023
novo_nordisk_flags_large

In a highly unusual move, the UK pharmaceutical industry’s trade body has suspended the membership of Danish diabetes giant Novo Nordisk (NOV: N).

It is only the eighth time in the past 40 years that the Association of the British Pharmaceutical Industry (ABPI) has taken such a strict measure.

The suspension, which will be in place for two years, is due to what the group calls “serious breaches” of its code of practice.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical